阿托伐他汀联合曲美他嗪治疗老年冠心病左心功能不全疗效及安全性评价

Effect and safety evaluation of atorvastatin combined with trimetazidine on left ventricular dysfunction in elderly patients with coronary heart disease

目的观察阿托伐他汀联合曲美他嗪治疗老年冠心病左心功能不全的治疗效果,并评价其安全性。方法将90例老年冠心病左心功能不全患者并随机分为试验组和对照组各45例。对照组患者给予常规治疗,试验组在常规治疗的基础上给予阿托伐他汀与曲美他嗪进行治疗。比较2组患者服药2年后的治疗效果;同时检查患者在治疗前后左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)以及左心室收缩末期内径(LVESD)变化情况,并评估患者NYHA心功能分级;另外密切关注患者在治疗期间出现的不良反应。结果试验组总有效率为93.3%高于对照组的75.6%,差异有统计学意义(P<0.05)。与治疗前比较,治疗后2组患者LVEF均升高,LVEDD、LVESD均降低,且试验组变化幅度大于对照组,差异均有统计学意义(P<0.05)。试验组Ⅰ、Ⅱ级患者的所占比例明显高于对照组,差异有统计学意义(P<0.05)。2组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论阿托伐他汀联合曲美他嗪治疗老年冠心病左心功能不全的治疗效果较好,且安全性较高,值得推广。

Objective To investigate the effects of atorvastatin combined with trimetazidine on left ventricular dysfunction in elderly patients with coronary heart disease,and to evaluate its safety.Methods 90 cases of elderly patients with coronary heart disease and left ventricular dysfunction were randomly divided into eXperimental group and control group,each of 45 cases.The patients in control group were treated with conventional therapy.On the basis of conventional treatment,eXperimental group was treated with atorvastatin and trimetazidine.Compared the therapeutic effect of two groups of patients after two years of treatment.before and after treatment;the left ventricular ejection fraction（LVEF）,left ventricular end diastolic diameter（LVEDD） and left ventricular end-systolic diameter（LVESD） were measured.Evaluated the NYHA cardiac function rating;Paid close attention to the patient during the treatment of adverse reactions.Results The total effective rate of eXperimental group was 93.3% higher than 75.6% of control group,the difference was statistically significant（P〈0.05）.Compared with before treatment,the LVEF was increased in both groups,LVEDD and LVESD were decreased,and the change of eXperimental group was greater than that of control group,the difference was statistically significant（P〈0.05）.The proportion of Ⅰand Ⅱ patients in eXperimental group were significantly higher than those in control group,the difference were statistically significant（P〈0.05）.There was no significant difference in the incidence of adverse reactions between the two groups（P〉0.05）.Conclusion Treatment of atorvastatin combined with trimetazidine on left ventricular dysfunction of elderly patients with coronary heart disease is better,and the safety is high,worthy of promotion.